Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Compare
Compare
Traded in other countries / regions
LLY.Argentina
•
LLYC.Austria
•
LILY34.Brazil
•
LLY.France
•
LLY.Germany
•
LLY.Mexico
•
LLY.Switzerland
•
LEL.UK
•
LLY.USA
Description
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 1.77 | |||||
| Debt-to-EBITDA | 1.9 | |||||
| Interest Coverage | 25.09 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.08 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.3 | |||||
| 3-Year EBITDA Growth Rate | 18.1 | |||||
| 3-Year EPS without NRI Growth Rate | 26.1 | |||||
| 3-Year FCF Growth Rate | 34.6 | |||||
| 3-Year Book Growth Rate | 0.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 18.98 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 7.44 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.23 | |||||
| 9-Day RSI | 22.17 | |||||
| 14-Day RSI | 32.43 | |||||
| 6-1 Month Momentum % | 35.05 | |||||
| 12-1 Month Momentum % | 23.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | |||||
| Quick Ratio | 0.98 | |||||
| Cash Ratio | 0.19 | |||||
| Days Inventory | 186.45 | |||||
| Days Sales Outstanding | 75.51 | |||||
| Days Payable | 76.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.21 | |||||
| Dividend Payout Ratio | 0.58 | |||||
| 3-Year Dividend Growth Rate | 14.8 | |||||
| Forward Dividend Yield % | 1.3 | |||||
| 5-Year Yield-on-Cost % | 2.07 | |||||
| 3-Year Average Share Buyback Ratio | 3.4 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.4 | |||||
| Operating Margin % | 28.82 | |||||
| Net Margin % | 20.9 | |||||
| ROE % | 77.76 | |||||
| ROA % | 12.85 | |||||
| ROIC % | 21.61 | |||||
| ROC (Joel Greenblatt) % | 75.35 | |||||
| ROCE % | 20.84 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 45.24 | |||||
| Forward PE Ratio | 36.23 | |||||
| PE Ratio without NRI | 45.24 | |||||
| Shiller PE Ratio | 65.31 | |||||
| Price-to-Owner-Earnings | 69.43 | |||||
| PEG Ratio | 2.34 | |||||
| PS Ratio | 9.35 | |||||
| PB Ratio | 30.7 | |||||
| Price-to-Free-Cash-Flow | 47.06 | |||||
| Price-to-Operating-Cash-Flow | 33.99 | |||||
| EV-to-EBIT | 42.49 | |||||
| EV-to-Forward-EBIT | 34.09 | |||||
| EV-to-EBITDA | 34.52 | |||||
| EV-to-Forward-EBITDA | 29.48 | |||||
| EV-to-Revenue | 10.24 | |||||
| EV-to-Forward-Revenue | 10.33 | |||||
| EV-to-FCF | 51.58 | |||||
| Price-to-Projected-FCF | 4.13 | |||||
| Price-to-Median-PS-Value | 2.22 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.97 | |||||
| Earnings Yield (Greenblatt) % | 2.35 | |||||
| Forward Rate of Return (Yacktman) % | 21.4 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:LLY
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29,322.8 | ||
| EPS (TTM) ($) | 6.66 | ||
| Beta | 0.4 | ||
| Volatility % | 27.74 | ||
| 14-Day RSI | 32.43 | ||
| 14-Day ATR ($) | 7.660928 | ||
| 20-Day SMA ($) | 323.9555 | ||
| 12-1 Month Momentum % | 23.84 | ||
| 52-Week Range ($) | 220.2 - 335.33 | ||
| Shares Outstanding (Mil) | 950.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||